- •Claude Opus 4.8 Fast argues HOLD because The long thesis remains intact: LLY is at a dense support/HVN cluster with 30-min momentum turning up from oversold, fundamentals are strong (35% margins, +25.9% last EPS surprise), and fresh July 14 analyst upgrades (JPM $1400, Bernstein $1385) reaffirm upside well beyond the $1237 target. The Teva/Forteo trigger is a legacy-licensing dispute, not a core weight-loss franchise threat, so the structural driver is unchanged.
- •What changed: Price drew down from $1185 entry to $1154.50 (at the effective stop) on a Teva-lawsuit-revival trigger and sector-wide healthcare weakness; offsetting this, multiple fresh July 14 analyst upgrades ($1385-$1400 targets) landed and 30-min momentum began turning up from oversold at support.
The long thesis remains intact: LLY is at a dense support/HVN cluster with 30-min momentum turning up from oversold, fundamentals are strong (35% margins, +25.9% last EPS surprise), and fresh July 14 analyst upgrades (JPM $1400, Bernstein $1385) reaffirm upside well beyond the $1237 target. The Teva/Forteo trigger is a legacy-licensing dispute, not a core weight-loss franchise threat, so the structural driver is unchanged.
The original thesis for LLY remains intact despite the recent pullback. The stock is testing critical support levels near $1142.83-$1155.00, which align with high-volume nodes and technical support. Analyst upgrades and Lilly's strong fundamentals, including its leadership in GLP-1 drugs and Alzheimer's research, support a bullish outlook. The upcoming US CPI event could act as a catalyst for broader market stabilization, and LLY's defensive characteristics may help it outperform in a volatile environment.
The original long thesis remains intact because the Teva lawsuit targets Forteo (an older osteoporosis drug), not LLY's core growth drivers (GLP-1s, Alzheimer's). Multiple analyst upgrades today including Bernstein's $1,385 PT confirm the fundamental outlook is strengthening, not deteriorating. The 30m timeframe shows oversold RSI turning up with MACD histogram rising, suggesting the selling pressure is exhausting at the HVN support cluster, positioning for a bounce toward the $1237 target within the remaining 8-day horizon.
No model argued for EXIT.
- →Price loses the $1147.95/$1142.83 support cluster on the CPI print or continued sector weakness, the effective stop at $1155.00 is breached and confirmed, and the down-leg extends toward POC $1116.27 — closing off the path back through overhead resistance to the $1237 target.
Individual Model Review
The long thesis remains intact: LLY is at a dense support/HVN cluster with 30-min momentum turning up from oversold, fundamentals are strong (35% margins, +25.9% last EPS surprise), and fresh July 14 analyst upgrades (JPM $1400, Bernstein $1385) reaffirm upside well beyond the $1237 target. The Teva/Forteo trigger is a legacy-licensing dispute, not a core weight-loss franchise threat, so the structural driver is unchanged.
The long thesis remains intact: LLY is at a dense support/HVN cluster with 30-min momentum turning up from oversold, fundamentals are strong (35% margins, +25.9% last EPS surprise), and fresh July 14 analyst upgrades (JPM $1400, Bernstein $1385) reaffirm upside well beyond the $1237 target. The Teva/Forteo trigger is a legacy-licensing dispute, not a core weight-loss franchise threat, so the structural driver is unchanged.
▼ Click to expandPrice sits exactly on the effective stop $1155.00 with 4h/1day momentum still falling and MACD negative; a break of the $1147/$1142 support on the imminent CPI print would confirm trend continuation toward POC $1116.27. If the stop is decisively lost the target path closes and the trade should be cut.
▼ Click to expandThe original long thesis remains intact because the Teva lawsuit targets Forteo (an older osteoporosis drug), not LLY's core growth drivers (GLP-1s, Alzheimer's). Multiple analyst upgrades today including Bernstein's $1,385 PT confirm the fundamental outlook is strengthening, not deteriorating. The 30m timeframe shows oversold RSI turning up with MACD histogram rising, suggesting the selling pressure is exhausting at the HVN support cluster, positioning for a bounce toward the $1237 target within the remaining 8-day horizon.
The original long thesis remains intact because the Teva lawsuit targets Forteo (an older osteoporosis drug), not LLY's core growth drivers (GLP-1s, Alzheimer's). Multiple analyst upgrades today including Bernstein's $1,385 PT confirm the fundamental outlook is strengthening, not deteriorating. The 30m timeframe shows oversold RSI turning up with MACD histogram rising, suggesting the selling pressure is exhausting at the HVN support cluster, positioning for a bounce toward the $1237 target within the remaining 8-day horizon.
▼ Click to expandThe position has hit the $1155.00 stop level, which is the defined invalidation point for the original thesis. The 4h timeframe shows deteriorating momentum with RSI at 40 and falling, MACD histogram deepening, and price below the lower Bollinger Band. The Teva lawsuit revival introduces legal overhang uncertainty that could persist, and with only 8 days remaining in the horizon, the probability of recovering to the $1237 target from a -2.5% loss position has materially diminished.
▼ Click to expandThe original thesis for LLY remains intact despite the recent pullback. The stock is testing critical support levels near $1142.83-$1155.00, which align with high-volume nodes and technical support. Analyst upgrades and Lilly's strong fundamentals, including its leadership in GLP-1 drugs and Alzheimer's research, support a bullish outlook. The upcoming US CPI event could act as a catalyst for broader market stabilization, and LLY's defensive characteristics may help it outperform in a volatile environment.
The original thesis for LLY remains intact despite the recent pullback. The stock is testing critical support levels near $1142.83-$1155.00, which align with high-volume nodes and technical support. Analyst upgrades and Lilly's strong fundamentals, including its leadership in GLP-1 drugs and Alzheimer's research, support a bullish outlook. The upcoming US CPI event could act as a catalyst for broader market stabilization, and LLY's defensive characteristics may help it outperform in a volatile environment.
▼ Click to expandThe position has weakened due to sector-wide pressure and a pullback to the stop level. If support at $1142.83-$1155.00 fails to hold, the original thesis would be invalidated, and the stop would be triggered. Additionally, if the broader market weakens further or the Teva lawsuit introduces unexpected risks, LLY could break down, making the risk/reward less favorable.
▼ Click to expandRun Summary
Intraday discovery triggered reanalysis on LLY. Verdict: HOLD (0/3 EXIT). Conviction: 76.